Among them, immune checkpoint blockade therapy represented by PD-1/PD-L1 inhibitors (nivolumab) and CTLA-4 inhibitors (ipilimumab) has shown encouraging therapeutic effects in the treatment of various malignancies, such as non-small cell lung cancer (NSCLC) and melanoma, etc. [46]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.